Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
SINGAPORE, Oct 24, 2017 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that U.S. biomedical subsidiary Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
Global Biolife has established a collaboration with top U.S. candy manufacturer Quality Candy Company LLC for the development, manufacture and global distribution of Laetose.
Developed by Mr Daryl L.Thompson, Global BioLife Director of Scientific Initiatives, Laetose is a functional sugar with a 30% to 50% lower calorie-count than regular sugar, possesses low glycemic properties, and also assists in mitigating inflammatory responses.
According to a World Health Organisation report released in Oct '17, the number of obese children aged 5 to 19 rose globally more than ten-fold from 11mil in 1975 to 124mil in 2016. The World Health Organisation report said that countries should seek to reduce consumption of cheap, ultra-processed, calorie-dense nutrition-poor foods.
Studies have shown that excessive sugar consumption is the primary cause of modern diseases such as cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity. While sugar is not toxic, the human body perceives it as such and, in turn, initiates pro-inflammatory responses. Laetose could help mitigate such reactions by reducing the rate of glucose absorption throughout the body.
Quality Candy has a Safe Quality Food ("SQF") Level 3 - Excellent certified manufacturing facility and is a leading manufacturer and distributer of high-quality candy with distribution in locations across the globe. They will utilize their state-of-the-art facility and expertise to manufacture Laetose according to the unique formula discovered by Global BioLife.
"In this day and age, we should be exploring ways to make smarter foods. Our Laetose modified sugar has been designed specifically for this purpose," said Global BioLife's Mr Thompson, a pioneering natural products scientist cited, amongst others, for his achievements in organic and carbohydrate chemistry.
Mr Chan Heng Fai, Executive Chairman of SeD, said: "Cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity have become a global epidemic. SeD has invested in Global BioLife as a think tank designed to research and develop smarter consumer products to reverse or mitigate this growing trend."
"Quality Candy has been on a quest for over a decade, looking for a natural sugar substitute," said Mr Jim Gist, Chief Revenue Officer of Quality Candy. "This product is finally the breakthrough our industry needed to improve existing reduced-calorie and sugar-free products and help consumers around the world live a healthier lifestyle."
The market for a safe and affordable alternative to sugar is growing due to increasing awareness of health risks associated with the excessive consumption of refined sugar. Although Laetose is marketed as an alternative usable in everything from baking to cooking, and as a tabletop sweetener, the ultimate goal is to infuse Laetose into the multibillion-dollar beverage industry. Unlike other natural-based and artificial sweeteners widely used in beverages, Laetose's unique patent-pending formula has no aftertaste.
"Due to the perceived toxicity of prolonged use of artificial sweeteners and the inability to use them as a direct replacement for sugar in baking and many beverages, we believe our product will have a direct advantage. We believe that the world is looking for a way to maintain sweetness while avoiding the negative effects of sugar and we intend to provide the solution," Mr Thompson added.
Dr Peggy Tang, Global BioLife CEO, said: "Laetose is our first step in creating smarter foods. We have confidence that our collaboration with industry leader Quality Candy will enable us to accomplish our goal."
About Singapore eDevelopment Ltd (SGX:40V)
Incorporated on 9 Sept 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd [SGE.SP; SINE.SP] is involved in property development and investment primarily in the United States and Western Australia; information technology-related businesses; development, research, testing, manufacturing, licensing and distribution of biomedical products; and investment activities. For more information, please visit www.SeD.com.sg or mail : [email protected].
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., in turn a wholly-owned direct subsidiary of Singapore eDevelopment Ltd, a company listed on the Singapore Exchange. The remaining shares of Global BioLife Inc. are held by Global Research & Discovery Group Scientific LLC ("GRDGS") and ASX-listed Holista CollTech Ltd with 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com.
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
NEC Solution Innovators Establishes "FonesLife," a healthcare business company that contributes to extending healthy life expectancy
Jul 09, 2020 14:34 JST
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 12:20 JST
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 12:11 JST
"Corolla Meets SUV"--Toyota Unveils Corolla Cross in Thailand, The New Compact SUV with Strength and Functionality to the Corolla Series
Jul 09, 2020 10:59 JST
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 14:33 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 14:16 JST
HSPP Announces Corporate Name Change to Honda India Power Products Limited
Jul 07, 2020 14:37 JST
Lexus Premieres New LS
Jul 07, 2020 13:31 JST
HOYA and Hitachi Announce Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
Jul 06, 2020 17:39 JST
Announcement of Absorption-type Merger (Simplified Merger and Short-form Merger) of DENSO IT Solutions Inc.
Jul 06, 2020 16:34 JST
JGA North is Ready for Service
Jul 06, 2020 15:30 JST
Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy
Jul 06, 2020 15:11 JST
Toyota Reproduces and Sells Spare Parts for 2000GT
Jul 06, 2020 13:37 JST
Fujitsu Embarks Towards 'New Normal', Redefining Working Styles for its Japan Offices
Jul 06, 2020 11:47 JST
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
Jul 06, 2020 09:33 JST
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
Jul 06, 2020 09:05 JST
NEC and JAMSTEC Develop AI-based System for Measuring Microplastics in the Ocean
Jul 03, 2020 11:30 JST
Fujitsu Revamps Corporate Philosophy 'FUJITSU Way' to Achieve Our Purpose
Jul 01, 2020 14:22 JST
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
Jul 01, 2020 14:02 JST
Toyota Launches New Acceleration Suppression System
Jul 01, 2020 13:48 JST